迈微医疗完成亿元级A+轮融资

Core Insights - Maiwei Medical announced the completion of a significant A+ round financing amounting to hundreds of millions of RMB [1] - The financing round was led by Yuanhe Origin, with participation from Zhengxin Valley Capital and existing shareholders Tianfeng Capital and Shumuc Venture [1] - Huaxing Capital served as the exclusive financial advisor for this financing round [1] Fund Utilization - The raised funds will be primarily used to accelerate the commercialization of the core product, the NxPFA® nanosecond pulsed electric field ablation system [1] - The company aims to deepen the layout of comprehensive cardiac electrophysiology solutions centered around nsPFA technology [1] - The funds will also support the multi-center registration clinical research and subsequent registration application for the industry's first adjustable acoustic field renal denervation (muRDN) system in the field of hypertension intervention treatment [1]